Perspective on potential clinical applications of recombinant human interleukin-7

Claude Sportes, Ronald E. Gress, Crystal L. Mackall

Research output: Chapter in Book/Report/Conference proceedingConference contribution

16 Citations (Scopus)

Abstract

Interleukin-7 has critical and nonredundant roles in T cell development, hematopoiesis, and postdevelopmental immune functions as a prototypic homeostatic cytokine. Based on a large body of preclinical evidence, it may have multiple therapeutic applications in immunodeficiency states, either physiologic (immuno-senescence), pathologic (HIV) or iatrogenic (postchemotherapy and posthematopoietic stem cell transplant) and may have roles in immune reconstitution or enhancement of immunotherapy. Early clinical development trials in humans show that, within a short time, rhIL-7 administration results in a marked preferential expansion of both naive and memory CD4 and CD8 T cell pools with a tendency toward enhanced CD8 expansion. As a result, lymphopenic or normal older hosts develop an expanded circulating T cell pool with a profile that resembles that seen earlier in life with increased T cell repertoire diversity. These results, along with a favorable toxicity profile, open a wide perspective of potential future clinical applications.

Original languageEnglish (US)
Title of host publicationCytokine Therapies Novel Approaches for Clinical Indications
PublisherBlackwell Publishing Inc.
Pages28-38
Number of pages11
ISBN (Print)9781573317832
DOIs
StatePublished - Jan 1 2009
Externally publishedYes

Publication series

NameAnnals of the New York Academy of Sciences
Volume1182
ISSN (Print)0077-8923
ISSN (Electronic)1749-6632

Fingerprint

Interleukin-7
T-cells
T-Lymphocytes
Transplants
Hematopoiesis
Stem cells
Immunotherapy
Toxicity
Stem Cells
Clinical Trials
HIV
Cytokines
Data storage equipment
Cells
Therapeutics

Keywords

  • Cytokine
  • Interleukin
  • T cell

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this

Sportes, C., Gress, R. E., & Mackall, C. L. (2009). Perspective on potential clinical applications of recombinant human interleukin-7. In Cytokine Therapies Novel Approaches for Clinical Indications (pp. 28-38). (Annals of the New York Academy of Sciences; Vol. 1182). Blackwell Publishing Inc.. https://doi.org/10.1111/j.1749-6632.2009.05075.x

Perspective on potential clinical applications of recombinant human interleukin-7. / Sportes, Claude; Gress, Ronald E.; Mackall, Crystal L.

Cytokine Therapies Novel Approaches for Clinical Indications. Blackwell Publishing Inc., 2009. p. 28-38 (Annals of the New York Academy of Sciences; Vol. 1182).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Sportes, C, Gress, RE & Mackall, CL 2009, Perspective on potential clinical applications of recombinant human interleukin-7. in Cytokine Therapies Novel Approaches for Clinical Indications. Annals of the New York Academy of Sciences, vol. 1182, Blackwell Publishing Inc., pp. 28-38. https://doi.org/10.1111/j.1749-6632.2009.05075.x
Sportes C, Gress RE, Mackall CL. Perspective on potential clinical applications of recombinant human interleukin-7. In Cytokine Therapies Novel Approaches for Clinical Indications. Blackwell Publishing Inc. 2009. p. 28-38. (Annals of the New York Academy of Sciences). https://doi.org/10.1111/j.1749-6632.2009.05075.x
Sportes, Claude ; Gress, Ronald E. ; Mackall, Crystal L. / Perspective on potential clinical applications of recombinant human interleukin-7. Cytokine Therapies Novel Approaches for Clinical Indications. Blackwell Publishing Inc., 2009. pp. 28-38 (Annals of the New York Academy of Sciences).
@inproceedings{a4865f85070143cead682054943bc09f,
title = "Perspective on potential clinical applications of recombinant human interleukin-7",
abstract = "Interleukin-7 has critical and nonredundant roles in T cell development, hematopoiesis, and postdevelopmental immune functions as a prototypic homeostatic cytokine. Based on a large body of preclinical evidence, it may have multiple therapeutic applications in immunodeficiency states, either physiologic (immuno-senescence), pathologic (HIV) or iatrogenic (postchemotherapy and posthematopoietic stem cell transplant) and may have roles in immune reconstitution or enhancement of immunotherapy. Early clinical development trials in humans show that, within a short time, rhIL-7 administration results in a marked preferential expansion of both naive and memory CD4 and CD8 T cell pools with a tendency toward enhanced CD8 expansion. As a result, lymphopenic or normal older hosts develop an expanded circulating T cell pool with a profile that resembles that seen earlier in life with increased T cell repertoire diversity. These results, along with a favorable toxicity profile, open a wide perspective of potential future clinical applications.",
keywords = "Cytokine, Interleukin, T cell",
author = "Claude Sportes and Gress, {Ronald E.} and Mackall, {Crystal L.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1111/j.1749-6632.2009.05075.x",
language = "English (US)",
isbn = "9781573317832",
series = "Annals of the New York Academy of Sciences",
publisher = "Blackwell Publishing Inc.",
pages = "28--38",
booktitle = "Cytokine Therapies Novel Approaches for Clinical Indications",

}

TY - GEN

T1 - Perspective on potential clinical applications of recombinant human interleukin-7

AU - Sportes, Claude

AU - Gress, Ronald E.

AU - Mackall, Crystal L.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Interleukin-7 has critical and nonredundant roles in T cell development, hematopoiesis, and postdevelopmental immune functions as a prototypic homeostatic cytokine. Based on a large body of preclinical evidence, it may have multiple therapeutic applications in immunodeficiency states, either physiologic (immuno-senescence), pathologic (HIV) or iatrogenic (postchemotherapy and posthematopoietic stem cell transplant) and may have roles in immune reconstitution or enhancement of immunotherapy. Early clinical development trials in humans show that, within a short time, rhIL-7 administration results in a marked preferential expansion of both naive and memory CD4 and CD8 T cell pools with a tendency toward enhanced CD8 expansion. As a result, lymphopenic or normal older hosts develop an expanded circulating T cell pool with a profile that resembles that seen earlier in life with increased T cell repertoire diversity. These results, along with a favorable toxicity profile, open a wide perspective of potential future clinical applications.

AB - Interleukin-7 has critical and nonredundant roles in T cell development, hematopoiesis, and postdevelopmental immune functions as a prototypic homeostatic cytokine. Based on a large body of preclinical evidence, it may have multiple therapeutic applications in immunodeficiency states, either physiologic (immuno-senescence), pathologic (HIV) or iatrogenic (postchemotherapy and posthematopoietic stem cell transplant) and may have roles in immune reconstitution or enhancement of immunotherapy. Early clinical development trials in humans show that, within a short time, rhIL-7 administration results in a marked preferential expansion of both naive and memory CD4 and CD8 T cell pools with a tendency toward enhanced CD8 expansion. As a result, lymphopenic or normal older hosts develop an expanded circulating T cell pool with a profile that resembles that seen earlier in life with increased T cell repertoire diversity. These results, along with a favorable toxicity profile, open a wide perspective of potential future clinical applications.

KW - Cytokine

KW - Interleukin

KW - T cell

UR - http://www.scopus.com/inward/record.url?scp=73849138583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73849138583&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.2009.05075.x

DO - 10.1111/j.1749-6632.2009.05075.x

M3 - Conference contribution

SN - 9781573317832

T3 - Annals of the New York Academy of Sciences

SP - 28

EP - 38

BT - Cytokine Therapies Novel Approaches for Clinical Indications

PB - Blackwell Publishing Inc.

ER -